nach oben

International Journal of Diabetes in Developing Countries

Erschienen in:

17.10.2016 | Original Article

Effect of community management of diabetes mellitus on patients with type 2 diabetes mellitus concomitant with depression

verfasst von: Ke Xiaoyun, Zhai Hailong, Wang Qingzhi

Erschienen in: International Journal of Diabetes in Developing Countries | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

The objective of the study was to explore the effect of management of type 2 diabetes mellitus (T2DM) concomitant with depression in a community setting. Ninety-one cases of patients with T2DM concomitant with depression were selected as study subjects and were randomly divided into two groups, 45 cases as the control group treated with comprehensive treatment for diabetes and 46 cases as the observation group received management of T2DM concomitant with depression besides the above treatments the control group received. After 3 months, body mass index (BMI), fasting plasma glucose (FPG), postprandial two-hour plasma glucose (2hPG), glycosylated hemoglobin (HbA1c), and Hamilton depression scale (HAMD scoring) were compared between the two groups. While BMI in the observation group had no significant difference compared with the control group, FPG, 2hPG, HbA1c, and HAMD scoring in the observation group were significantly higher than those in the control group (P<0.05). Standardized management of T2DM concomitant with depression in a community setting can improve the treatment effect for patients with T2DM concomitant with depression.

World Health Organization. Global report on diabetes. Geneva: WHO Press; 2016.

Okoro CA, Denny CH, Greenlund KJ, et al. Risk factors for heart disease and stroke among diabetic persons, by disability status. J Diabetes Complicat. 2005;19(4):201–6.CrossRefPubMed

American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Association; 2013.CrossRef

Tomita T, Yasui-Furukori N, Nakagami T, et al. Therapeutic reference range for plasma concentrations of paroxetine in patients with major depressive disorders. Ther Drug Monit. 2014;36(4):480–5.CrossRefPubMed

Roy T, Lloyd CE. Epidemiology of depression and diabetes: a systematic review. J Affect Disord. 2012;142(Suppl):S8–21.CrossRefPubMed

Brown LC, Majumdar SR, Newman SC, Johnson JA. History of depression increases risk of type 2 diabetes in younger adults. Diabetes Care. 2005;28(5):1063–7.CrossRefPubMed

Campayo A, de Jonge P, Roy JF, Saz P, de la Camara C, Quintanilla MA, et al. Depressive disorder and incident diabetes mellitus: the effect of characteristics of depression. Am J Psychiatry. 2010;167(5):580–8.CrossRefPubMed

Kumari M, Head J, Marmot M. Prospective study of social and other risk factors for incidence of type 2 diabetes in the Whitehall II study. Arch Int Medicine. 2004;164(17):1873–80.CrossRef

Therrien F, Drapeau V, Lalonde J, et al. Awakening cortisol response in lean, obese, and reduced obese individuals: effect of gender and fat distribution. Obesity. 2007;15(2):377–85.CrossRefPubMed

10.

The World Health Organization. The Global Burden of Disease: 2004 Update. 2008.

11.

Baumeister H, Hutter N, Bengel J. Psychological and pharmacological interventions for depression in patients with diabetes mellitus and depression: an abridged Cochrane review. Diabet Med. 2014;31(7):773–86.CrossRefPubMed

12.

van der Feltz-Cornelis CM, Nuyen J, Stoop C, Chan J, Jacobson AM, Katon W, et al. Effect of interventions for major depressive disorder and significant depressive symptoms in patients with diabetes mellitus: a systematic review and meta-analysis. Gen Hosp Psychiatry. 2010;32(4):380–95.CrossRefPubMed

13.

Hillary RB, Knashawn HM, de Vries HF, et al. Integrated management of type 2 diabetes mellitus and depression treatment to improve medication adherence: a randomized controlled trial. Ann Fam Med. 2012;10(1):15–22.CrossRef

14.

World Health Organization. 1999.World Health Organization: definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Appendix 2 summary of WHO diagnostic criteria for diabetes and intermediate hyperglycaemia. Geneva.

15.

Petrak F, Baumeister H, Skinner TC, et al. Depression and diabetes: treatment and health-care delivery. Lancet Diabetes Endocrinol. 2015;3(6):472–85.CrossRefPubMed

16.

Agardh E, Allebeck P, Hallqvist J, Moradi T, Sidorchuk A. Type 2 diabetes incidence and socio-economic position: a systematic review and meta-analysis. Int J Epidemiol. 2011;40:804–18.CrossRefPubMed

17.

Folb N, Lund C, Fairall LR, Timmerman V, Levitt NS, Steyn K, Bachmann MO. Socioeconomic predictors and consequences of depression among primary care attenders with noncommunicable diseases in the Western Cape, South Africa: cohort study within a randomised trial BMC Public Health 2015; 15:1194.

18.

Kyrou I, Tsigos C. Stress hormones: physiological stress and regulation of metabolism. Curr Opin Pharmacol. 2009;9:787–93.CrossRefPubMed

19.

Chrousos GP. Stress and disorders of the stress system. Nat Rev Endocrinol. 2009;5:374–81.CrossRefPubMed

20.

Herbert J, Goodyer IM, Grossman AB, Hastings MH, de Kloet ER, Lightman SL, Lupien SJ, Roozendaal B, Seckl JR. Do corticosteroids damage the brain? J Neuroendocrinol. 2006;18:393–411.CrossRefPubMed

21.

Moulton CD, Costafreda SG, Horton P, Ismail K, Fu CH. Meta-analyses of structural regional cerebral effects in type 1 and type 2 diabetes. Brain Imaging Behav. 2015;9:651–62.CrossRefPubMed

22.

Wang X, Bao W, Liu J, Ouyang YY, Wang D, Rong S, Xiao X, Shan ZL, Zhang Y, Yao P, Liu LG. Inflammatory markers and risk of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care. 2013;36:166–75.CrossRefPubMed

23.

Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27:24–31.CrossRefPubMed

24.

Crane PK, Walker R, Hubbard RA, et al. Glucose levels and risk of dementia. N Engl J Med. 2013;369(6):540–8.CrossRefPubMedPubMedCentral

25.

Tu k Y, Lin PY. Hypomania soon after shifting from paroxetine to agomelatine in a middle-aged woman with depression. Clin Neuropharmacol. 2014;37(3):82–3.CrossRefPubMed

Titel: Effect of community management of diabetes mellitus on patients with type 2 diabetes mellitus concomitant with depression
verfasst von: Ke Xiaoyun
Zhai Hailong
Wang Qingzhi
Publikationsdatum: 17.10.2016
Verlag: Springer India
Erschienen in: International Journal of Diabetes in Developing Countries / Ausgabe 4/2017
Print ISSN: 0973-3930
Elektronische ISSN: 1998-3832
DOI: https://doi.org/10.1007/s13410-016-0525-2

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2017

Comparative evaluation of clinical and inflammatory factors in response to the pharmacological managements in metabolic syndrome

On association between diabetes status and stature of individual in Bangladesh: an ordinal regression analysis

From obesity through immunity to type 2 diabetes mellitus

Zymogram profiling of myeloperoxidase in association with increased risk of infection susceptibility in diabetic foot ulcer

Increased risk of type 2 diabetes mellitus in the Maru Raika community of Rajasthan: a cross-sectional study

Glycaemic index: challenges in translating concept to practice